Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991-2012

Drug and Alcohol Dependence

Volumn 143, Issue 1, 2014, Pages 149-157

  Nosyk, Bohdan ^a,b,c   Li, Libo ^c   Evans, Elizabeth ^c   Urada, Darren ^c   Huang, David ^c   Wood, Evan ^a,d   Rawson, Richard ^c   Hser, Yih Ing ^c  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Detoxification treatment; Longitudinal; Methadone treatment; Opioid dependence

Indexed keywords

METHADONE; NARCOTIC AGENT;

ADULT; ARTICLE; DETOXIFICATION; FEMALE; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; OUTCOME ASSESSMENT; RETREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; ADOLESCENT; ECONOMICS; MENTAL HEALTH SERVICE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; TIME; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; CALIFORNIA; COMMUNITY MENTAL HEALTH SERVICES; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922402329     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.07.020     Document Type: Article

References (38)

1. Alter H.J., Liang T.J. Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann. Intern. Med. 2012, 156:317-318.
2. Amato L., Davoli M., Perucci C.A., Ferri M., Faggiano F., Mattick R.P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J. Subst. Abuse Treat. 2005, 28:321-329.
3. Amato L., Minozzi S., Davoli M., Vecchi S., Ferri M., Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst. Rev. 2004, 4:CD005031.
4. Andrews C.M., D'Aunno T.A., Pollack H.A., Freidmann P.D. Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs. Med. Care Res. Rev. 2014, 71:43-60.
5. Ball J.C., Ross A. The Effectiveness of Methadone Maintenance Treatment 1991, Springer-Verlag, New York.
6. Breslow N.E., Clayton D.G. Approximate inference in generalized linear mixed models. J. Am. Stat. Assoc. 1993, 88:9-25.
7. California Alcohol and Drug Programs, 2005. California Outcomes Measurement Systems (CalOMS) Treatment Data Compliance Standards. (accessed 15.07.13). http://www.adp.ca.gov/CalOMS/pdf/CalOMS_Data_Compliance.pdf.
8. California Department of Alcohol and Drug Programs, 2012. Indicators of Alcohol and Other Drug Abuse: FY 2010-11. (accessed 15.07.13). http://www.adp.ca.gov/oara/pdf/Indicators_Report_2010-11pdf.
9. California Department of Alcohol and Drug Programs, 2012. Research and Analysis: California Alcohol and Drug Programs. (accessed on 15.07.13). http://www.adp.ca.gov/oara/index.shtml.
10. Degenhardt L., Bucello C., Mathers B., Briegleb C., Ali H., Hickman M., McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011, 106:32-51.
11. Degenhardt L., Randall D., Hall W., Law M., Butler T., Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009, 105:9-15.
12. Faggiano F., Vigna-Taglianti F., Versino E., Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst. Rev. 2003, 3:CD002208.
13. Hser Y.I., Evans E., Ettner S., Huang D., Picazo R. The California Treatment Outcome Project Supplement to the Final Report 2003, UCLA Integrated Substance Abuse Programs, Los Angeles, CA.
14. Jones C.M. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers-United States, 2002-2004 and 2008-2010. Drug Alcohol Depend. 2013, 132:95-100.
15. Kleber H.D. Methadone maintenance 4 decades later: thousands of lives saved but still controversial. J. Am. Med. Assoc. 2008, 300:2303-2305.
16. McCarthy J.J., Borders O.T. Limit setting on drug abuse in methadone maintenance patients. Am. J. Psychiatry 1985, 142:1419-1423.
17. McLellan A.T., Lewis D.C., O'Brien C.P., Kleber H.D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. J. Am. Med. Assoc. 2000, 284:1689-1695.
18. Moore B.A., Fiellin D.A., Barry D.T., Sullivan L.E., Chawarski M.C., O'Connor P.G., Schottenfeld R.S. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J. Gen. Intern. Med. 2007, 22:527-530.
19. Nosyk B., Anglin M.D., Brecht M.L., Lima V.D., Hser Y.I. Characterizing durations of heroin abstinence in the California Civil Addict Program: results from a 33-year natural history study. Am. J. Epidemiol. 2013, 177:675-682.
20. Nosyk B., Anglin M.D., Brissette S., Kerr T., Marsh D., Schackman B.R., Wood E., Montaner J.S.G. A call for evidence-based medicine for the treatment of opioid dependence in North America. Health Aff. (Millwood) 2013, 32:1462-1469.
21. Nosyk B., Guh D.P., Bansback N.J., Oviedo-Joekes E., Brissette S., Marsh D.C., Meikleham E., Schechter M.T., Anis A.H. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. Can. Med. Assoc. J. 2012, 184:E317-E328.
22. Nosyk B., MacNab Y.C., Sun H., Marsh D.C., Fischer B., Schechter M.T., Anis A.H. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am. J. Epidemiol. 2009, 170:783-792.
23. O'Connor P.G. Methods of detoxification and their role in treating patients with opioid dependence. J. Am. Med. Assoc. 2005, 294:961-963.
24. Peles E., Schreiber S., Adelson M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend. 2006, 82:211-217.
25. Raudenbush S.W., Bryk A.S. Hierarchical Linear Models: Applications and Data Analysis Methods 2003, Sage, Newbury Park, CA. 2nd ed.
26. Rawson R., Crevecouer D. Los Angeles County Evaluation System Annual Report 2005, UCLA Integrated Substance Abuse Programs, Los Angeles, CA.
27. Rosenblum A., Joseph H., Fong C., Kipnis S., Cleland C., Portenoy R.K. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. J. Am. Med. Assoc. 2003, 289:2370-2378.
28. Stephenson, D.K., California Society of Addiction Medicine, 2008. Guideline for Physicians Working in California Opioid Treatment Programs. (accessed 15.07.13). http://www.csam-asam.org/sites/default/files/csam_otpguideline_oct08pdf.
29. Substance Abuse and Mental Health Services Administration, 2006. Detoxification and Substance Abuse Treatment: A Treatment Improvement Protocol TIP 45. (accessed 19.07.13). http://store.samhsa.gov/product/TIP-45-Detoxification-and-Substance-Abuse-Treatment/SMA12-4131.
30. Results from the 2009 National Survey on Drug Use and Health: Volume 1 Summary of National Findings 2009, Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services, Rockville, MD.
31. Substance Abuse and Mental Health Services Administration, 2010. The National Survey on Substance Abuse Treatment Services. (accessed 16.06.12). http://www.samhsa.gov/data/2k10/225/225OpiodTx2k10Web.pdf.
32. Substance Abuse and Mental Health Services Administration, 2011. Medication-Assisted Treatment for Opioid Addiction: 2010 State Profiles, Substance Abuse and Mental Health Services Administration (accessed 08.07.13). http://www.dpt.samhsa.gov/pdf/MedicationAssistedTreatmentForOpioidAddiction_2010StateProfiles03pdf.
33. Therneau T.M., Grambsch P.T. Modeling Survival Data: Extending the Cox Model 2000, Springer-Verlag Publishers, New York.
34. Urada D., Fan J., Rawson R. Data analysis report. Evaluation Services to Enhance the Data Management System in California. Prepared for the Department of Alcohol and Drug Programs, California Health and Human Services Agency 2010, UCLA Integrated Substance Abuse Programs, Los Angeles, CA, (pp. 5-25).
35. US Food and Drug Administration, 2002. Subutex and Suboxone Approved To Treat Opiate Dependence. (accessed 15.10.13). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm191521htm.
36. Volkow N.D., Montaner J.S.G. The urgency of providing comprehensive and integrated treatment for substance abusers with HIV. Health Aff. 2011, 30:1411-1419.
37. Zaric G.S., Barnett P.G., Brandeau M.L. HIV transmission and the cost-effectiveness of methadone maintenance. Am. J. Public Health 2000, 90:1100-1111.
38. Zarkin G.A., Dunlap L.J., Hicks K.A., Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ. 2005, 14:1133-1150.